naltrexone and Obesity

naltrexone has been researched along with Obesity in 135 studies

Research

Studies (135)

Timeframe	Studies, this research(%)	All Research%
pre-1990	14 (10.37)	18.7374
1990's	13 (9.63)	18.2507
2000's	14 (10.37)	29.6817
2010's	80 (59.26)	24.3611
2020's	14 (10.37)	2.80

Authors

Authors	Studies
Barbosa, MP; Carneiro, MG; Costa, JA; de Freitas, MFL; de Souza, IA; de Vasconcelos, DAA; do Nascimento, E; Dos Santos Oliveira, L; Lopes de Souza, S; Matos, RJB; Roberto da Silva, G	1
Correa, OMT; Doretto-Silva, L; Morreale, S; Nassis, C; Petri, G; Santos, JFRD; Scudeler, MA; Veridiano, JM	1
Fineberg, SK; Grilo, CM; Gueorguieva, R; Ivezaj, V; Lydecker, JA; Moreno, JO	1
Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K	1
Aronson, JK; Heneghan, CJ; Lee, JJ; Mahtani, KR; Onakpoya, IJ	1
Gorelik, B; Gorelik, E; Hirsh-Raccah, B; Masarwa, R; Matok, I; Perlman, A	1
Capasso, A; De Biasio, V; Di Munzio, W; Foggia, G; Milano, W	1
Barrea, L; Colao, A; Laudisio, D; Muscogiuri, G; Pugliese, G; Savastano, S	1
Acevedo-Mackey, D; Acharjee, N; Akhtar, K; Al-Buriahi, MS; Amandi, A; An, Y; Anjum, NA; Asgari, Q; Badiei, B; Baez Vasquez, AY; Bagley, GD; Bahreini, MS; Bajelan, S; Baluja, MQ; Barbieri, MA; Batalha, MA; Bettiol, H; Bhattarai, U; Biset, JC; Bjerg, M; Björnsson, BT; Boag, AM; Borthwick, MS; Boukhris, I; Bragança, MLBM; Breves, JP; Britz-McKibbin, P; Broaddus, RR; Burnell, JE; Camargo, CA; Campo, M; Carlsen, KL; Catchpole, B; Cavalli, L; Chai, C; Chanakya, HN; Chang, AYH; Chantada, A; Chen, W; Chen, X; Chen, Y; Cheng, ZL; Chenoweth, DA; Chhetri, S; Coelho, CCNDS; Coker, ES; Cole, MA; Coniglio, A; Connor, TR; Corbishley, A; D'Arienzo, M; da Silva, AAM; Dai, Y; de Oliveira, BR; Dignac, MF; Dong, A; Dottino, JA; Duo, J; Einarsdottir, IE; Ekanayake, EMDNK; El Fels, L; El Hayany, B; El Shahawy, O; Elliott, RJR; Fabrizi, E; Farkas, K; Fellman, B; Fenoglio, D; Ferrario, M; Flögel, F; Fujiogi, M; Gamage, BD; Ganson, KT; Gao, X; Gärtner, S; Gautam, A; Gautam, S; Gaze, WH; Gosse, JA; Graham, DW; Graham, PA; Guastella, G; Guerrero, S; Gul, M; Guo, B; Guo, X; Gupta, VK; Hafidi, M; Halland, A; Han, W; Hardisty, M; Hasegawa, K; Hess, ST; Heydari, R; Hillary, LS; Holm, R; Huang, L; Jaleh, B; Jayasundara, JASB; Ji, X; Jiang, L; Jones, DL; Kac, G; Kebaili, I; Kelley, JB; Kelum, SHP; Kennedy, LJ; Khan, NA; Khazalpour, S; Khuntia, HK; Kinney, MS; Kommedal, Ø; Koomhin, P; Krawczyk, N; Kæstel, T; Lakmal, MAC; Li, H; Li, K; Li, R; Li, S; Li, W; Li, X; Li, Y; Liang, L; Lin, Y; Lippo, E; Liu, B; Liu, F; Liu, J; Liu, X; Liu, Y; Lodha, D; Loose, DS; López-Meza, P; Lu, F; Lu, KH; Lu, Y; Luo, Y; Ma, B; Malham, SK; Masood, A; Matan, N; McCormick, SD; McDonald, JE; McKenzie, LJ; Melendez, BD; Mikaeili, F; Mir, IR; Mirjalili, MH; Moreno, KP; Moura, IB; Müller, S; Nagata, JM; Nasri, A; Nasrollahzadeh, M; Navarro-Jiménez, E; Nie, E; Nielsen, CU; Nielsen, S; Nøhr, MK; Obeng, B; Odetayo, AA; Ortiz-Barrios, M; Ozgen, C; Pan, X; Parisi, ML; Paskavitz, AL; Patel, AK; Pedersen, M; Pontarollo, N; Potts, CM; Price, C; Pu, Y; Quénéa, K; Rahimi Khonakdari, M; Rather, BA; Raut, P; Regish, AM; Reible, DD; Rezadoost, H; Rizzati, M; Roviello, GN; Roviello, V; Rumpel, C; Sang, J; Sangroula, S; Saraiva, MDCP; Sarker, A; Sayyed, MI; Segoshi, A; Sehar, Z; Shao, X; Shaw, D; Shaw, L; Shekhawat, NS; Shim, JK; Shokouhimehr, M; Short, A; Soliman, PT; Songsamoe, S; Springer-Miller, RH; Stenstad, T; Strobl, E; Sun, R; Syme, H; Thai, L; Tian, G; Tofighi, B; Tonguc, B; Tuyiringire, D; Ulaganathan, N; Ulvestad, E; Varacca, A; Vergalli, S; Verma, DK; Villmones, HC; Wang, D; Wang, H; Wang, J; Wang, L; Wang, M; Wang, S; Wang, Y; Wang, Z; Weedon-Fekjær, H; Weller, SR; West, BE; Wilcox, MH; Wu, W; Wufuer, R; Xia, S; Xiang, H; Xu, H; Yan, L; Yang, RK; Yang, Y; Yates, MS; Ye, Q; Yin, H; Yin, Y; Yuan, Y; Yucesan, M; Yue, W; Zeng, W; Zhang, C; Zhang, D; Zhang, H; Zhang, L; Zhang, Q; Zhang, Y; Zhou, B; Zhou, Y; Zhu, Y; Zhu, Z	1
Brown, SA; Izzy, M; Watt, KD	1
Grilo, CM; Gueorguieva, R; Lydecker, JA; Morgan, PT	1
Lee, SY; Tak, YJ	1
Abawi, O; van den Akker, ELT; van der Valk, ES; van der Voorn, B; van Rossum, EFC; Welling, MS	1
Barakat, M; Blavignac, J; Burrows, M; Camacho, F; Christensen, RAG; Gould, E; Kamran, E; Wharton, S; Yin, P	1
Blundell, JE; Dalton, M; Duarte, C; Finlayson, G; Halseth, AE; Walsh, B	1
Wilding, JPH	2
Dunayevich, E; Guerdjikova, AI; Halseth, AE; McElroy, SL; Shan, K; Walsh, B	1
Golden, A	1
Hsu, EA; Miller, JL; Perez, FA; Roth, CL	1
Bersoux, S; Byun, TH; Chaliki, SS; Poole, KG	1
Nadolsky, KZ	1
Barrea, L; Cataldi, M; Colao, A; Guida, B; Muscogiuri, G; Savastano, S; Taglialatela, M	1
Acevedo, LM; Apovian, CM; Dunayevich, E; Greenway, FL; McElroy, SL; Pi-Sunyer, X	1
Bello, NT	1
Chatzis, P; Dinas, K; Makris, V; Pratilas, GC; Sotiriadis, A; Tziomalos, K	1
Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H	1
Billes, SK; Burns, C; Dunayevich, E; Fujioka, K; Greenway, FL; Gupta, AK; Kim, D; Smith, SR	1
Howland, RH	2
Caparelli, EC; Dunayevich, E; Telang, F; Tomasi, D; Volkow, ND; Wang, GJ; Wang, R	1
Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R	1
Adam, T; Dallman, M; Daubenmier, J; Epel, E; Hecht, FM; Kristeller, J; Lustig, RH; Woolley, J	1
Billes, SK; Cowley, MA; Sinnayah, P	1
Brouwer, S; Cowen, PJ; Harmer, CJ; McCabe, C; McCutcheon, R; Murray, E	1
Bello, NT; Verpeut, JL	1
Nakazato, M; Ueno, H	1
Aldhoon-Hainerová, I; Hainer, V	1
Hainer, V	1
Aronne, LJ	1
Cunningham, JW; Wiviott, SD	1
Albert, L; Caixàs, A; Capel, I; Rigla, M	1
Citrome, L	2
Rubio, MA	1
Buehler, AM	1
Mehr, SR; Zimmerman, MP	1
Dahiya, N; Kakkar, AK	1
Fujioka, K	1
Acree, M; Adler, N; Bacchetti, P; Brown, RR; Dallman, M; Daubenmier, J; Epel, ES; Hecht, FM; Laraia, B; Lustig, RH; Mason, AE; Moran, PJ	1
Nau, JY	1
Greig, SL; Keating, GM	1
Bragg, R; Crannage, E	1
Adler, N; Dallman, M; Daubenmier, J; Epel, ES; Gearhardt, AN; Hecht, FM; Kiernan, M; Laraia, B; Lustig, RH; Mason, AE; Puterman, E	1
Chen, S; Gilder, K; Greenway, FL; Klassen, P; Kolotkin, RL	1
Ali, KF; Aronne, LJ; Shukla, AP	1
Apovian, CM	1
Megyeri, J; Nuffer, W; Trujillo, JM	1
Psaty, BM; Sharfstein, JM	1
Bakris, G; Buse, JB; Nissen, SE; Perez, A; Prcela, L; Smith, SR; Wadden, T; Wolski, KE	1
Lewis, RJ; Tolles, J	1
Wise, J	1
Camilleri, M; Chandar, AK; Dulai, PS; Khera, R; Loomba, R; Murad, MH; Prokop, LJ; Singh, S; Wang, Z	1
Alfaris, N; Kyle, TK; Nadai, J; Stanford, FC	1
Fujioka, K; Gilder, K; Greenway, FL; O'Neil, PM; Plodkowski, R; Walsh, B	1
Dybala, C; Foreyt, JP; Halseth, AE; Herrmann, K; Hong, K; Lam, H	1
Braverman-Panza, J; Fujioka, K	1
Backman, SB; Christou, NV; Price, RC; Schweinhardt, P; Stone, L	1
Halpern, B; Mancini, MC	1
Kreek, MJ; Low, MJ; Rubinstein, M; Zhou, Y	1
Brown, WA; Man Lee, CC; Oldfield, BJ; Stefanidis, A	1
Fujioka, K; Gilder, K; Halseth, A; Shan, K; Walsh, B	1
Aronne, LJ; Igel, LI; Kumar, RB; Saunders, KH	1
Curry, SA	1
Anderson, JW; Atkinson, RL; Cowley, MA; Dunayevich, E; Fujioka, K; Gadde, KM; Greenway, FL; Gupta, AK; Guttadauria, M; O'Neil, P; Schumacher, D; Smith, D; Tollefson, GD; Weber, E; Whitehouse, MJ	1
Chau, DL; Nguyen, L; Nguyen, Q; Plodkowski, RA; St Jeor, S; Sundaram, U	1
Reece, AS	1
Fujioka, K; Lee, MW	1
Padwal, R	1
Cowley, MA; Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Tollefson, G	1
Billes, SK; Dunayevich, E; Erickson, JS; Katz, BB; Oskooilar, N; Tollefson, G; Wilcox, CS	1
Berthoud, HR; Lenard, NR; Zheng, H	1
Kaplan, LM	1
Dunayevich, E; Erickson, JS; Foreyt, JP; Foster, GD; Hill, JO; Kim, DD; Klein, S; Maier, HN; O'Neil, PM; Perri, MG; Pi-Sunyer, FX; Rock, CL; Wadden, TA	1
Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Kim, DD; Mudaliar, S; Plodkowski, RA	1
Astrup, A	1
Hatzitolios, AI; Katsiki, N; Mikhailidis, DP	1
Billes, SK; Greenway, FL	1
Faria, AM; Halpern, A; Halpern, B	1
Bray, GA; Ryan, DH	1
Gwinn, KM; Hurren, KM; Makowski, CT	1
Bello, NT; Liang, NC; Moran, TH	1
Goldfine, AB; Hiatt, WR; Thomas, A	1
Gosden, J; Heal, DJ; Smith, SL	1
Mercer, SL	1
Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J	1
Athanacio, J; Clapper, JR; D'Souza, L; Griffin, PS; Parkes, DG; Roth, JD; Wittmer, C	1
Jarosz, PA; Metzger, BL	1
Gray, RW; Yeomans, MR	1
Chen, RZ; Fong, TM; Huang, RR; MacNeil, DJ; Shen, CP	1
Farrell, PA; Loomis, JL; Rodd, DW	1
Guido, M; Lanzone, A; Romualdi, D	1
Coscina, DV; Jarosz, PA; Kessler, JT; Sekhon, P	1
Jarosz, PA	1
Luciano, M; Pert, CB; Recant, L; Voyles, NR	1
Baile, CA; McLaughlin, CL	1
Billington, CJ; Briggs, J; Grace, MK; Kotz, CM; Levine, AS	1
Bodnar, RJ; Bowen, WD; Cole, JL; Leventhal, L; Pasternak, GW	1
Cobelli, C; De Palo, C; Federspil, G; Macor, C; Rossi, E; Ruggeri, A; Vettor, R	1
Shaw, WN	1
Caruso, A; Cucinelli, F; Fulghesu, AM; Lanzone, A; Mancuso, S	1
Caruso, A; De Marinis, L; Fulghesu, AM; Lanzone, A; Mancini, A; Pavone, V; Valle, D; Villa, P	1
Bianchi, A; De Luca, AM; De Marinis, L; Fulghesu, AM; Lanzone, A; Mancini, A; Mancuso, S; Valle, D; Villa, P	1
Barton, C; Bray, GA; Ookuma, K; York, DA	1
De Marinis, L; Fulghesu, AM; Lanzone, A; Mancini, A; Mancuso, S; Pavone, V; Valle, D; Villa, P	1
Marín-Bivens, CL; Olster, DH	1
Acosta, A; Baptista, T; Colasante, C; de Mendoza, S; de Quijada, M; Hernández, L; Lacruz, A; Mendoza, JM	1
Bersi, C; Fruzzetti, F; Genazzani, AR; Parrini, D; Ricci, C	1
de Zwaan, M; Mitchell, JE	1
Alger, SA; Bigaouette, JM; Howard, LJ; Michalek, AV; Schwalberg, MD	1
Cohen, Y; Jacquot, C; Orosco, M; Robert, JJ; Rouch, C	1
Beaufrere, B; Chatelain, P; de Parscau, L; François, R; Loeuille, GA; Ythier, H	1
Shrager, EE; Spiegel, TA; Stellar, E	1
Baile, CA; Gingerich, RL; McLaughlin, CL; Michel, ME	1
Allen, JI; Atkinson, RL; Knopman, DS; Malcolm, RJ; Mitchell, JE; Morley, JE; Pfohl, DN	1
Apfelbaum, M; Bertière, MC; Betoulle, D; Mandenoff, A	1
Morrison, MF; O'Brien, CP; Shrager, EE; Spiegel, TA; Stellar, E; Stunkard, AJ	1
Gannon, M; Hatsukami, D; Levine, AS; Mitchell, JE; Morley, JE; Pfohl, D	1
Bracco, EF; Hashim, SA; Kissileff, HR; Maggio, CA; Pfohl, DN; Presta, E; Vasselli, JR	1
Counts, C; Currey, HS; Malcolm, R; O'Neil, PM; Riddle, FE; Sexauer, JD	1
Hatsukami, DK; Levine, AS; Mitchell, JE; Morgan, SF; Morley, JE	1
Atkinson, RL; Berke, LK; Bibbs, ML; Drake, CR; Kaiser, DL; Williams, FL	1

Reviews

44 review(s) available for naltrexone and Obesity

Article	Year
Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. British journal of clinical pharmacology, 2020, Volume: 86, Issue:4 Topics: Bupropion; Drug Combinations; Humans; Naltrexone; Obesity	2020
Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy. Endocrine, metabolic & immune disorders drug targets, 2020, Volume: 20, Issue:8 Topics: Anti-Obesity Agents; Bupropion; Epidemics; Global Health; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Precision Medicine; Weight Loss	2020
New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. Minerva endocrinologica, 2020, Volume: 45, Issue:2 Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Endocrinology; Humans; Liraglutide; Naltrexone; Nutritional Sciences; Obesity	2020
International journal of disaster risk reduction : IJDRR, 2020, Volume: 49 Topics: Acyclic Monoterpenes; Adipose Tissue; Adolescent; Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollutants, Occupational; Amino Acid Transport Systems; Analgesics, Opioid; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Arthrobacter; Bacteria; Bacteriological Techniques; Benzaldehydes; Biodegradation, Environmental; Biofilms; Biological Transport; Biomarkers; Biomass; Bioreactors; Body Composition; Body Mass Index; Brassica; Brazil; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Caco-2 Cells; Cadmium; Calcium; Calcium Carbonate; Calcium Channels; Catalysis; Cell Degranulation; Cell Line; Cell Membrane; Chitosan; Chromatography, High Pressure Liquid; Chromium; Cobalt; Cohort Studies; Colony Count, Microbial; Composting; Copper; COVID-19; Cross-Sectional Studies; Cytoplasm; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diarrhea; Diethylhexyl Phthalate; Dose-Response Relationship, Drug; Drug Implants; Drug Stability; Drug Synergism; Electroplating; Endometrial Neoplasms; Endometrium; Environmental Monitoring; Environmental Restoration and Remediation; Estradiol; Estrogens; Feces; Female; Food Microbiology; Food Preservation; Fruit and Vegetable Juices; Gasotransmitters; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gene Expression Regulation, Developmental; Genetic Predisposition to Disease; Glutathione; Gold; Graphite; Growth Hormone; Harm Reduction; Hot Temperature; Humans; Hydrocortisone; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydrogen-Ion Concentration; Ileum; Imidazoles; Injections, Intraperitoneal; Insecticides; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 5; Insulin-Like Growth Factor I; Intestinal Absorption; Light; Lignin; Liver; Magnetics; Male; Manganese; Mast Cells; Melanoma; Membrane Potentials; Metals; Methadone; Microbial Viability; Microplastics; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Middle Aged; Mitochondrial Swelling; Molecular Dynamics Simulation; Monophenol Monooxygenase; Morocco; Naloxone; Naltrexone; Nanocomposites; Nanomedicine; Nanoparticles; Narcotic Antagonists; Neonicotinoids; Nitric Oxide; Nitro Compounds; Nitrogen; Nitrogen Compounds; Obesity; Obesity, Abdominal; Occupational Exposure; Ontario; Opiate Substitution Treatment; Opioid-Related Disorders; Oryza; Overweight; Oxidative Stress; Oxides; Oxygen; Perception; Photoelectron Spectroscopy; Plants; Plastics; Point Mutation; Polychlorinated Biphenyls; Polycyclic Aromatic Hydrocarbons; Potassium; Premenopause; Prodrugs; Prospective Studies; Protons; Pyrolysis; Qualitative Research; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Resins, Synthetic; Rhodamines; Risk Factors; ROC Curve; Salmo salar; SARS-CoV-2; Seawater; Severity of Illness Index; Sewage; Social Media; Soil; Soil Microbiology; Soil Pollutants; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Staining and Labeling; Stainless Steel; Steel; Stress, Physiological; Substance Abuse Treatment Centers; Symporters; T-Lymphocytes; Toluene; Triclosan; Ultraviolet Rays; Waist Circumference; Waste Disposal, Fluid; Wastewater; Water Purification; Welding; X-Ray Diffraction; Young Adult	2020
Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential. Hepatology (Baltimore, Md.), 2021, Volume: 73, Issue:5 Topics: Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Humans; Liraglutide; Liver Cirrhosis; Liver Transplantation; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Translational Science, Biomedical	2021
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Current obesity reports, 2021, Volume: 10, Issue:1 Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss	2021
Medication use for the treatment of diabetes in obese individuals. Diabetologia, 2018, Volume: 61, Issue:2 Topics: Animals; Benzazepines; Bupropion; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Lactones; Naltrexone; Obesity; Orlistat	2018
Current pharmacotherapies for obesity: A practical perspective. Journal of the American Association of Nurse Practitioners, 2017, Volume: 29, Issue:S1 Topics: Adult; Anti-Obesity Agents; Benzazepines; Female; Humans; Lactones; Liraglutide; Middle Aged; Naltrexone; Obesity; Orlistat; Phentermine; Risk Reduction Behavior; United States	2017
Pharmacotherapy for obesity: What you need to know. Cleveland Clinic journal of medicine, 2017, Volume: 84, Issue:12 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine	2017
Gender-related issues in the pharmacology of new anti-obesity drugs. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2019, Volume: 20, Issue:3 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Liraglutide; Male; Naltrexone; Obesity; Patient Selection; Sex Factors; Topiramate; Treatment Outcome; Weight Loss	2019
The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome. Folia medica, 2018, Dec-01, Volume: 60, Issue:4 Topics: Androgens; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Insulin Resistance; Liraglutide; Naltrexone; Obesity; Orlistat; Polycystic Ovary Syndrome; Weight Loss	2018
Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacological research, 2014, Volume: 84 Topics: Antidepressive Agents, Second-Generation; Bupropion; Drug Therapy, Combination; Energy Metabolism; Humans; Naltrexone; Narcotic Antagonists; Obesity; Weight Loss	2014
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert opinion on drug safety, 2014, Volume: 13, Issue:6 Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Humans; Naltrexone; Obesity; Weight Loss	2014
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3 Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Discovery; Energy Metabolism; Enzyme Inhibitors; Fructose; Glucagon-Like Peptide 1; Humans; Hypothalamus; Lactones; Lipase; Liraglutide; Metabolic Syndrome; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate	2014
Tolerability and safety of the new anti-obesity medications. Drug safety, 2014, Volume: 37, Issue:9 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Chemistry, Pharmaceutical; Drug-Related Side Effects and Adverse Reactions; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate	2014
Overview of new antiobesity drugs. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2014
Evolving directions in obesity management. The Journal of family practice, 2014, Volume: 63, Issue:7 Suppl Topics: Anti-Obesity Agents; Bupropion; Dopamine Uptake Inhibitors; Forecasting; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Liraglutide; Naltrexone; Narcotic Antagonists; Obesity; Receptors, Glucagon	2014
Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. Clinical cardiology, 2014, Volume: 37, Issue:11 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Fructose; Heart; Humans; Naltrexone; Obesity; Phentermine; Topiramate	2014
Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug design, development and therapy, 2014, Volume: 8 Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Naltrexone; Obesity	2014
Drug treatment of obesity: current status and future prospects. European journal of internal medicine, 2015, Volume: 26, Issue:2 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Drug Combinations; Drug Therapy, Combination; Fructose; Humans; Lactones; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate	2015
Safety and tolerability of medications approved for chronic weight management. Obesity (Silver Spring, Md.), 2015, Volume: 23 Suppl 1 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss	2015
Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain. Journal of psychosocial nursing and mental health services, 2015, Volume: 53, Issue:6 Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Liraglutide; Melatonin; Naltrexone; Obesity; Psychotropic Drugs; Weight Gain	2015
Naltrexone ER/Bupropion ER: A Review in Obesity Management. Drugs, 2015, Volume: 75, Issue:11 Topics: Adult; Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Humans; Naltrexone; Obesity; Overweight	2015
Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity. Expert review of clinical pharmacology, 2016, Volume: 9, Issue:1 Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Approval; Drug Combinations; Humans; Naltrexone; Obesity	2016
Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. Future cardiology, 2016, Volume: 12, Issue:2 Topics: Adult; Anti-Obesity Agents; Bupropion; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Naltrexone; Obesity; Weight Loss	2016
A Comparison of New Pharmacological Agents for the Treatment of Obesity. The Annals of pharmacotherapy, 2016, Volume: 50, Issue:5 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations; Fructose; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2016
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA, 2016, Jun-14, Volume: 315, Issue:22 Topics: Anti-Obesity Agents; Bayes Theorem; Benzazepines; Drug Combinations; Female; Fructose; Humans; Lactones; Liraglutide; Male; Middle Aged; Naltrexone; Obesity; Orlistat; Phentermine; Randomized Controlled Trials as Topic; Topiramate; Weight Loss	2016
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. Expert opinion on drug safety, 2017, Volume: 16, Issue:1 Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate	2017
Practical Use of Pharmacotherapy for Obesity. Gastroenterology, 2017, Volume: 152, Issue:7 Topics: Androgens; Anti-Obesity Agents; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Fructose; Humans; Hypoglycemic Agents; Hypogonadism; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Testosterone; Topiramate; Weight Gain	2017
Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:6 Topics: Animals; Bupropion; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Naltrexone; Obesity; Weight Loss	2009
Naltrexone for the treatment of obesity: review and update. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:11 Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Feeding Behavior; Humans; Naltrexone; Narcotic Antagonists; Obesity; Opioid Peptides; Weight Loss	2009
Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Current opinion in investigational drugs (London, England : 2000), 2009, Volume: 10, Issue:10 Topics: Administration, Oral; Animals; Appetite; Bupropion; Controlled Clinical Trials as Topic; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Drug Combinations; Energy Metabolism; Humans; Naltrexone; Narcotic Antagonists; Obesity; Weight Loss	2009
Pharmacologic therapies for obesity. Gastroenterology clinics of North America, 2010, Volume: 39, Issue:1 Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; Ephedrine; Fenfluramine; Humans; Lactones; Naltrexone; Obesity; Orlistat; Phentermine; Weight Gain; Weight Loss	2010
Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR. Drugs in R&D, 2010, Volume: 10, Issue:1 Topics: Animals; Anti-Obesity Agents; Bupropion; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Drug Combinations; Drug Evaluation, Preclinical; Drugs, Investigational; Humans; Naltrexone; Obesity	2010
Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? Annals of medicine, 2011, Volume: 43, Issue:4 Topics: Bupropion; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Naltrexone; Obesity; Weight Loss	2011
Combination therapy with naltrexone and bupropion for obesity. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:11 Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Drug Combinations; Humans; Naltrexone; Narcotic Antagonists; Obesity; Overweight; Weight Loss	2011
Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Obesity facts, 2011, Volume: 4, Issue:6 Topics: Anti-Obesity Agents; Bupropion; Diabetes Mellitus; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Naltrexone; Obesity; Quality of Life; Waist Circumference; Weight Loss	2011
A review of late-stage CNS drug candidates for the treatment of obesity. International journal of obesity (2005), 2013, Volume: 37, Issue:1 Topics: Anti-Obesity Agents; Bupropion; Central Nervous System Stimulants; Drug Administration Schedule; Drug Approval; Drug Combinations; Drug Design; Drugs, Investigational; Female; Guidelines as Topic; Humans; Male; Naltrexone; Obesity; Patient Selection; Phentermine; Receptor, Serotonin, 5-HT2C; Risk Factors; Risk Reduction Behavior; United Kingdom	2013
ACS chemical neuroscience molecule spotlight on contrave. ACS chemical neuroscience, 2011, Sep-21, Volume: 2, Issue:9 Topics: Anti-Obesity Agents; Bupropion; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Approval; Drug Combinations; Humans; Naltrexone; Obesity; Overweight; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Weight Loss	2011
Recent advancements in drug treatment of obesity. Clinical medicine (London, England), 2012, Volume: 12, Issue:5 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Weight Loss	2012
Opioid peptides and the control of human ingestive behaviour. Neuroscience and biobehavioral reviews, 2002, Volume: 26, Issue:6 Topics: Alcoholism; Appetite Regulation; Drinking Behavior; Feeding Behavior; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Obesity; Opioid Peptides; Receptors, Opioid; Reward; Substance-Related Disorders; Time Factors; Water Intoxication	2002
Role of opioid antagonists in the treatment of women with glucoregulation abnormalities. Current pharmaceutical design, 2006, Volume: 12, Issue:8 Topics: Clinical Trials as Topic; Endorphins; Female; Humans; Hyperinsulinism; Insulin Resistance; Menopause; Naloxone; Naltrexone; Narcotic Antagonists; Obesity; Polycystic Ovary Syndrome	2006
Opiate antagonists and eating behavior in humans: a review. Journal of clinical pharmacology, 1992, Volume: 32, Issue:12 Topics: Appetite Depressants; Dose-Response Relationship, Drug; Eating; Feeding and Eating Disorders; Feeding Behavior; Female; Humans; Male; Naloxone; Naltrexone; Narcotic Antagonists; Obesity	1992
[Hypothalamic dysfunction. 2 cases: the contribution of nuclear magnetic resonance, therapeutic trial of naltrexone]. Pediatrie, 1989, Volume: 44, Issue:3 Topics: Body Height; Body Weight; Child, Preschool; Feeding Behavior; Female; Fever; Humans; Hypernatremia; Hypothalamic Diseases; Hypothermia; Magnetic Resonance Imaging; Male; Naltrexone; Obesity; Pituitary Function Tests	1989

Trials

29 trial(s) available for naltrexone and Obesity

Article	Year
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. The American journal of psychiatry, 2022, 12-01, Volume: 179, Issue:12 Topics: Behavior Therapy; Binge-Eating Disorder; Bupropion; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Obesity; Treatment Outcome; Weight Loss	2022
Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study. Clinical therapeutics, 2021, Volume: 43, Issue:1 Topics: Adult; Anti-Obesity Agents; Binge-Eating Disorder; Body Weight; Bupropion; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Obesity; Pilot Projects; Treatment Outcome	2021
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring, Md.), 2013, Volume: 21, Issue:5 Topics: Adult; Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Feeding Behavior; Female; Humans; Hypertension; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Obesity; Overweight; Quality of Life; Risk Factors; Weight Loss	2013
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes care, 2013, Volume: 36, Issue:12 Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Body Weight; Bupropion; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Overweight; Retrospective Studies; Risk Factors; Treatment Outcome; Weight Loss; Young Adult	2013
Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity. Psychopharmacology, 2014, Volume: 231, Issue:22 Topics: Adult; Affect; Brain Mapping; Cerebrum; Double-Blind Method; Female; Food; Humans; Magnetic Resonance Imaging; Naltrexone; Narcotic Antagonists; Obesity; Reward; Taste; Young Adult	2014
Acute responses to opioidergic blockade as a biomarker of hedonic eating among obese women enrolled in a mindfulness-based weight loss intervention trial. Appetite, 2015, Volume: 91 Topics: Adult; Behavior, Addictive; Binge-Eating Disorder; Body Mass Index; Body Weight; Bulimia; Eating; Emotions; Female; Humans; Hydrocortisone; Middle Aged; Mindfulness; Motivation; Naltrexone; Narcotic Antagonists; Nausea; Obesity; Opioid Peptides; Receptors, Opioid; Reward; Stress, Psychological; Weight Reduction Programs	2015
Putting the brakes on the "drive to eat": Pilot effects of naltrexone and reward-based eating on food cravings among obese women. Eating behaviors, 2015, Volume: 19 Topics: Adult; Craving; Eating; Female; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Pilot Projects; Reward; Treatment Outcome; Young Adult	2015
Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity. Clinical obesity, 2015, Volume: 5, Issue:5 Topics: Adult; Aged; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Obesity; Quality of Life; Surveys and Questionnaires; Weight Loss; Young Adult	2015
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA, 2016, Mar-08, Volume: 315, Issue:10 Topics: Aged; Anti-Obesity Agents; Blood Pressure; Body Mass Index; Bupropion; Cardiovascular Diseases; Confidence Intervals; Confidentiality; Double-Blind Method; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Humans; Internet; Male; Middle Aged; Myocardial Infarction; Naltrexone; Obesity; Overweight; Patient Selection; Placebo Effect; Risk Factors; Sample Size; United States; Weight Reduction Programs	2016
The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. International journal of obesity (2005), 2016, Volume: 40, Issue:9 Topics: Adolescent; Adult; Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Obesity; Risk Factors; Treatment Outcome; Weight Loss; Young Adult	2016
Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes. Clinical obesity, 2016, Volume: 6, Issue:5 Topics: Adult; Anti-Obesity Agents; Body Mass Index; Bupropion; Combined Modality Therapy; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hypertension; Incidence; Lost to Follow-Up; Male; Naltrexone; Nausea; Obesity; Overweight; Patient Dropouts; Severity of Illness Index; United States; Weight Loss	2016
Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. Obesity (Silver Spring, Md.), 2017, Volume: 25, Issue:2 Topics: Adolescent; Adult; Body Weight; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Double-Blind Method; Exercise; Feeding Behavior; Female; Humans; Life Style; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Obesity; Weight Loss; Young Adult	2017
Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring, Md.), 2009, Volume: 17, Issue:1 Topics: Adult; Animal Feed; Animals; Antidepressive Agents; Bupropion; Disease Models, Animal; Drug Therapy, Combination; Fasting; Female; Humans; Male; Mice; Mice, Obese; Naltrexone; Narcotic Antagonists; Obesity; Overweight; United States; Weight Loss	2009
Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:12 Topics: Adolescent; Adult; Appetite; Bupropion; Cohort Studies; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Positron-Emission Tomography; Risk Factors; Weight Loss; Young Adult	2009
An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addictive behaviors, 2010, Volume: 35, Issue:3 Topics: Adult; Bupropion; Cotinine; Counseling; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Obesity; Overweight; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome; Weight Gain	2010
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:1 Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality Therapy; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Placebos; Treatment Outcome; Weight Loss	2011
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England), 2010, Aug-21, Volume: 376, Issue:9741 Topics: Adult; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Obesity; Overweight; Weight Loss	2010
Influence of opioids in hypothalamic nuclei on cold thermogenesis of lean and obese LA/N-cp rats. Obesity research, 1994, Volume: 2, Issue:3 Topics: Animals; Cold Temperature; Enkephalin, Leucine; Male; Naloxone; Naltrexone; Narcotic Antagonists; Obesity; Opioid Peptides; Oxygen Consumption; Paraventricular Hypothalamic Nucleus; Rats; Rats, Sprague-Dawley; Stress, Physiological; Thermogenesis	1994
Impact of long-term naltrexone treatment on growth hormone and insulin secretion in hyperandrogenic and normal obese patients. Metabolism: clinical and experimental, 1997, Volume: 46, Issue:5 Topics: Adult; Female; Glucose Tolerance Test; Growth Hormone-Releasing Hormone; Hormones; Human Growth Hormone; Humans; Hyperandrogenism; Insulin; Insulin Secretion; Naltrexone; Narcotic Antagonists; Obesity; Polycystic Ovary Syndrome; Reference Values; Time Factors	1997
Influence of chronic Naltrexone treatment on growth hormone and insulin secretion in obese subjects. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1997, Volume: 21, Issue:11 Topics: Adult; Body Mass Index; C-Peptide; Female; Glucose Tolerance Test; Human Growth Hormone; Humans; Insulin; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Naltrexone; Narcotic Antagonists; Obesity	1997
Effect of opioid blockade on insulin and growth hormone (GH) secretion in patients with polycystic ovary syndrome: the heterogeneity of impaired GH secretion is related to both obesity and hyperinsulinism. Fertility and sterility, 1999, Volume: 71, Issue:1 Topics: Adult; Area Under Curve; Female; Glucose Tolerance Test; Human Growth Hormone; Humans; Hyperinsulinism; Insulin; Naltrexone; Narcotic Antagonists; Obesity; Polycystic Ovary Syndrome	1999
Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertility and sterility, 2002, Volume: 77, Issue:5 Topics: Adult; Androgens; Blood Glucose; Body Mass Index; Drug Administration Schedule; Endocrine Glands; Fasting; Female; Gonadotropins; Humans; Hydrocortisone; Insulin; Insulin Resistance; Menstrual Cycle; Naltrexone; Narcotic Antagonists; Obesity; Polycystic Ovary Syndrome; Time Factors	2002
Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects. The American journal of clinical nutrition, 1991, Volume: 53, Issue:4 Topics: Adult; beta-Endorphin; Bulimia; Double-Blind Method; Female; Humans; Hyperphagia; Imipramine; Naltrexone; Obesity	1991
Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. NIDA research monograph, 1986, Volume: 67 Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Clinical Trials as Topic; Dementia; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Liver Function Tests; Middle Aged; Naltrexone; Obesity; Random Allocation	1986
High-dose naltrexone therapy and dietary counseling for obesity. Biological psychiatry, 1987, Volume: 22, Issue:1 Topics: Adult; Counseling; Diet, Reducing; Double-Blind Method; Humans; Liver Function Tests; Male; Middle Aged; Naltrexone; Obesity; Random Allocation	1987
Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men. Brain research bulletin, 1985, Volume: 14, Issue:6 Topics: Adult; Basal Metabolism; Body Weight; Clinical Trials as Topic; Drug Administration Schedule; Energy Intake; Feeding Behavior; Humans; Male; Naloxone; Naltrexone; Obesity	1985
A controlled trial of naltrexone in obese humans. International journal of obesity, 1985, Volume: 9, Issue:5 Topics: Adult; Body Weight; Clinical Trials as Topic; Female; Humans; Liver; Male; Middle Aged; Naltrexone; Obesity; Placebos; Random Allocation; Transaminases	1985
Effect of naltrexone on mood and cognitive functioning among overweight men. Biological psychiatry, 1986, Volume: 21, Issue:3 Topics: Adolescent; Adult; Affect; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Male; Middle Aged; Naltrexone; Obesity; Psychological Tests; Random Allocation	1986
Effects of long-term therapy with naltrexone on body weight in obesity. Clinical pharmacology and therapeutics, 1985, Volume: 38, Issue:4 Topics: Administration, Oral; Adult; Body Weight; Double-Blind Method; Drug Evaluation; Female; Humans; Liver Function Tests; Male; Middle Aged; Naltrexone; Obesity; Random Allocation; Sex Factors	1985

Other Studies

62 other study(ies) available for naltrexone and Obesity

Article	Year
Naltrexone/bupropion modifies weight, food intake, and Drd2 gene expression in rats. The Journal of endocrinology, 2022, 04-13, Volume: 253, Issue:3 Topics: Animals; Body Weight; Bupropion; Diet, High-Fat; Eating; Gene Expression; Naltrexone; Obesity; Rats; Rats, Wistar; Receptors, Dopamine D2; Tyrosine 3-Monooxygenase	2022
Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats. Einstein (Sao Paulo, Brazil), 2022, Volume: 20 Topics: Animals; Bupropion; Humans; Male; Naltrexone; Obesity; Rats; Rats, Wistar; Subcutaneous Fat; Topiramate	2022
Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:9 Topics: Bupropion; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Humans; Liraglutide; Naltrexone; Obesity; Overweight; Peptides; Proglucagon; Weight Loss	2023
The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database. International journal of obesity (2005), 2020, Volume: 44, Issue:5 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anti-Obesity Agents; Benzazepines; Cardiovascular Diseases; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Naltrexone; Obesity; Phentermine; United States; United States Food and Drug Administration	2020
[Pharmacotherapy for obesity]. Nederlands tijdschrift voor geneeskunde, 2021, 01-19, Volume: 165 Topics: Anti-Obesity Agents; Bariatric Surgery; Bupropion; Combined Modality Therapy; Drug Combinations; Drug Therapy, Combination; Humans; Hunger; Life Style; Liraglutide; Naltrexone; Obesity; Satiation; Treatment Outcome; Weight Loss	2021
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. International journal of obesity (2005), 2021, Volume: 45, Issue:8 Topics: Aged; Anti-Obesity Agents; Body Weight; Bupropion; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incretins; Male; Middle Aged; Naltrexone; Obesity; Randomized Controlled Trials as Topic; Weight Loss	2021
Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample. International journal of obesity (2005), 2017, Volume: 41, Issue:8 Topics: Adult; Bupropion; Clinical Trials, Phase III as Topic; Craving; Dopamine Uptake Inhibitors; Feeding Behavior; Female; Food Preferences; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Psychometrics; Surveys and Questionnaires; Treatment Outcome; Weight Loss	2017
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study. Advances in therapy, 2017, Volume: 34, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Binge-Eating Disorder; Bupropion; Comorbidity; Depressive Disorder, Major; Female; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Overweight	2017
Oxytocin and Naltrexone Successfully Treat Hypothalamic Obesity in a Boy Post-Craniopharyngioma Resection. The Journal of clinical endocrinology and metabolism, 2018, 02-01, Volume: 103, Issue:2 Topics: Administration, Intranasal; Administration, Oral; Child; Craniopharyngioma; Humans; Hypothalamic Diseases; Male; Naltrexone; Neurosurgical Procedures; Obesity; Oxytocin; Pituitary Neoplasms; Treatment Outcome	2018
Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population. Military medicine, 2018, 03-01, Volume: 183, Issue:3-4 Topics: Alcohol Deterrents; Appetite Depressants; Benzazepines; Cohort Studies; Drug Therapy; Humans; Incretins; Liraglutide; Military Personnel; Naltrexone; Obesity; Phentermine; Retrospective Studies	2018
Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK. Clinical obesity, 2018, Volume: 8, Issue:3 Topics: Anti-Obesity Agents; Bariatric Surgery; Body Weight Maintenance; Bupropion; Health Services; Humans; Life Style; Liraglutide; Naltrexone; Obesity; Primary Health Care; Specialization; State Medicine; United Kingdom; Weight Loss; Weight Reduction Programs	2018
Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis. International journal of obesity (2005), 2019, Volume: 43, Issue:10 Topics: Anti-Obesity Agents; Bupropion; Double-Blind Method; Drug Combinations; Humans; Mood Disorders; Naltrexone; Obesity; Overweight; Prospective Studies; Randomized Controlled Trials as Topic	2019
Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert opinion on drug safety, 2019, Volume: 18, Issue:7 Topics: Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Humans; Naltrexone; Obesity	2019
Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:9 Topics: Absorptiometry, Photon; Adiposity; Analysis of Variance; Body Composition; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Humans; Intra-Abdominal Fat; Male; Middle Aged; Naltrexone; Obesity; Tomography, X-Ray Computed; Treatment Outcome; Weight Loss	2013
Therapies for obesity and medication-associated weight gain. Journal of psychosocial nursing and mental health services, 2013, Volume: 51, Issue:5 Topics: Animals; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Chronic Disease; Combined Modality Therapy; Diet, Reducing; Disease Models, Animal; Drug Combinations; Exercise; Fructose; Humans; Mood Disorders; Naltrexone; Obesity; Overweight; Phentermine; Psychotic Disorders; Randomized Controlled Trials as Topic	2013
Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues. International journal of obesity (2005), 2014, Volume: 38, Issue:5 Topics: Adolescent; Adult; Appetite; Bupropion; Cues; Diet; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Ghrelin; Humans; Hypothalamus; Leptin; Magnetic Resonance Imaging; Meals; Naltrexone; Obesity; Peptide YY; Treatment Outcome; Weight Loss	2014
A new biomarker of hedonic eating? A preliminary investigation of cortisol and nausea responses to acute opioid blockade. Appetite, 2014, Volume: 74 Topics: Adiposity; Adult; Biomarkers; Body Mass Index; Bulimia; Cross-Sectional Studies; Eating; Energy Intake; Feeding Behavior; Female; Humans; Hydrocortisone; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Obesity; Overweight; Receptors, Opioid; Surveys and Questionnaires	2014
Contrave--a combination of bupropion and naltrexone for weight loss. The Medical letter on drugs and therapeutics, 2014, Nov-10, Volume: 56, Issue:1455 Topics: Anti-Obesity Agents; Bupropion; Drug Approval; Drug Combinations; Drug Interactions; Humans; Naltrexone; Obesity; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Weight Loss	2014
Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out. International journal of clinical practice, 2014, Volume: 68, Issue:12 Topics: Benzazepines; Bupropion; Drug Combinations; Drug Prescriptions; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2014
Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2014, Volume: 61, Issue:10 Topics: Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Europe; Fructose; Humans; Naltrexone; Obesity; Phentermine; Product Surveillance, Postmarketing; Topiramate; United States; United States Food and Drug Administration	2014
Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug design, development and therapy, 2015, Volume: 9 Topics: Anti-Obesity Agents; Bupropion; Humans; Naltrexone; Obesity	2015
Nonincretin drugs in later-stage development. The American journal of managed care, 2014, Volume: 20, Issue:1 Spec No. Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Drug Labeling; Drugs, Investigational; Fructose; Humans; Naltrexone; Obesity; Phentermine; United States; United States Food and Drug Administration	2014
[Mysimba, an American appetite suppressant and the logic of the single European market]. Revue medicale suisse, 2015, Apr-15, Volume: 11, Issue:470 Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Naltrexone; Obesity; Overweight	2015
Review of pharmacotherapy options for the management of obesity. Journal of the American Association of Nurse Practitioners, 2016, Volume: 28, Issue:2 Topics: Benzazepines; Bupropion; Disease Management; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; United States	2016
Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A Study Interrupted. JAMA, 2016, Mar-08, Volume: 315, Issue:10 Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Female; Humans; Male; Naltrexone; Obesity	2016
Time-to-Event Analysis. JAMA, 2016, Mar-08, Volume: 315, Issue:10 Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Female; Humans; Male; Naltrexone; Obesity	2016
Company is blamed for early halt of trial into obesity treatment. BMJ (Clinical research ed.), 2016, Mar-08, Volume: 352 Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Female; Humans; Male; Naltrexone; Obesity	2016
A new era of addiction treatment amplifies the stigma of disease and treatment for individuals with obesity. International journal of obesity (2005), 2016, Volume: 40, Issue:9 Topics: Anti-Obesity Agents; Attitude of Health Personnel; Behavior, Addictive; Bupropion; Drug Therapy, Combination; Humans; Naltrexone; Obesity; Patient Education as Topic; Social Stigma; Stereotyping; United States	2016
Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management. The Journal of family practice, 2016, Volume: 65, Issue:7 Suppl Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Guidelines as Topic; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Primary Health Care; Risk Factors; Treatment Outcome; Weight Loss	2016
Opioid-receptor antagonism increases pain and decreases pleasure in obese and non-obese individuals. Psychopharmacology, 2016, Volume: 233, Issue:23-24 Topics: Adult; beta-Endorphin; Case-Control Studies; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Obesity; Opioid Peptides; Pain Threshold; Pleasure; Sensory Thresholds	2016
Hypothalamic-specific proopiomelanocortin deficiency reduces alcohol drinking in male and female mice. Genes, brain, and behavior, 2017, Volume: 16, Issue:4 Topics: Adrenal Insufficiency; Alcohol Drinking; Animals; Ethanol; Female; Genotype; Hypothalamus; Male; Mice; Mice, Knockout; Naltrexone; Obesity; Pro-Opiomelanocortin	2017
Improving efficacy of the adjustable gastric band: studies of the use of adjuvant approaches in a rodent model. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 2017, Volume: 13, Issue:2 Topics: Adipose Tissue, Brown; Animals; Anti-Obesity Agents; Blood Glucose; Body Composition; Body Fat Distribution; Body Temperature; Bupropion; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Eating; Energy Metabolism; Gastroplasty; Glucose Intolerance; Injections, Subcutaneous; Insulin Resistance; Laparoscopy; Male; Naltrexone; Obesity; Physical Conditioning, Animal; Rats, Sprague-Dawley; Thermogenesis; Thyroxine; Weight Loss	2017
Obesity Epidemic: Pharmaceutical Weight Loss. Rhode Island medical journal (2013), 2017, Mar-01, Volume: 100, Issue:2 Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Drug Combinations; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Weight Loss	2017
Chronic ulcers caused by injection of substances: healing aided by naltrexone. Archives of dermatology, 2009, Volume: 145, Issue:4 Topics: Chronic Disease; Diabetes Mellitus, Type 1; Drug Implants; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Skin Ulcer; Substance Abuse, Intravenous; Wound Healing	2009
Chronic suppression of μ-opioid receptor signaling in the nucleus accumbens attenuates development of diet-induced obesity in rats. International journal of obesity (2005), 2010, Volume: 34, Issue:6 Topics: Animals; Body Weight; Dietary Fats; Dietary Sucrose; Food Preferences; Food, Formulated; Male; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Obesity; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu	2010
Is cardiometabolic risk improved by weight-loss drugs? Lancet (London, England), 2010, Aug-21, Volume: 376, Issue:9741 Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Naltrexone; Obesity; Risk Factors	2010
Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination? International journal of clinical practice, 2010, Volume: 64, Issue:11 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Body Mass Index; Bupropion; Delayed-Action Preparations; Drug Combinations; Drug Synergism; Female; Humans; Male; Middle Aged; Naltrexone; Numbers Needed To Treat; Obesity; Randomized Controlled Trials as Topic; Weight Loss; Young Adult	2010
New obesity pill: new hopes, old fears. Lancet (London, England), 2010, Dec-18, Volume: 376, Issue:9758 Topics: Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Drug Approval; Drug Combinations; Exercise; Feeding Behavior; Humans; Life Style; Naltrexone; Narcotic Antagonists; Obesity; Seizures; Suicidal Ideation; United States; United States Food and Drug Administration	2010
Bupropion/naltrexone fixed-dose combination for the treatment of obesity. Drugs of today (Barcelona, Spain : 1998), 2011, Volume: 47, Issue:8 Topics: Animals; Bupropion; Clinical Trials as Topic; Drug Combinations; Humans; Naltrexone; Obesity	2011
Drug treatment of obesity. The Psychiatric clinics of North America, 2011, Volume: 34, Issue:4 Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Body Weight; Bupropion; Child; Drug Approval; Drug Combinations; Energy Intake; Exenatide; Female; Fructose; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Lactones; Male; Metformin; Naltrexone; Narcotic Antagonists; Obesity; Orlistat; Patient Compliance; Peptides; Randomized Controlled Trials as Topic; Sympathomimetics; Topiramate; United States; United States Food and Drug Administration; Venoms	2011
Additive feeding inhibitory and aversive effects of naltrexone and exendin-4 combinations. International journal of obesity (2005), 2013, Volume: 37, Issue:2 Topics: Animals; Appetite Depressants; Body Weight; Drug Interactions; Drug Therapy, Combination; Eating; Exenatide; Hypoglycemic Agents; Male; Naltrexone; Obesity; Peptides; Rats; Rats, Sprague-Dawley; Taste; Venoms; Weight Loss	2013
What cost weight loss? Circulation, 2012, Mar-06, Volume: 125, Issue:9 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cyclobutanes; Fructose; Humans; Naltrexone; Obesity; Phentermine; Risk Assessment; Risk Factors; Topiramate; Weight Loss	2012
Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models. European journal of pharmacology, 2013, Jan-05, Volume: 698, Issue:1-3 Topics: Animals; Appetite Depressants; Body Composition; Body Weight; Bupropion; Diet; Drug Interactions; Eating; Gene Expression Regulation; Gene Knockout Techniques; Islet Amyloid Polypeptide; Male; Mice; Naltrexone; Obesity; Rats; Time Factors	2013
The effect of opioid antagonism on food intake behavior and body weight in a biobehavioral model of obese binge eating. Biological research for nursing, 2002, Volume: 3, Issue:4 Topics: Animals; Body Weight; Brain; Bulimia; Energy Intake; Feeding Behavior; Hyperphagia; Injections, Intraventricular; Models, Animal; Naltrexone; Narcotic Antagonists; Obesity; Rats; Rats, Zucker; Satiation	2002
Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice. Brain research, 2004, Mar-05, Volume: 999, Issue:2 Topics: Animals; Appetite Regulation; Body Weight; Brain; Cannabinoid Receptor Modulators; Cannabinoids; Dose-Response Relationship, Drug; Drug Synergism; Homeostasis; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Obesity; Opioid Peptides; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1	2004
Conditioned place preferences (CPPs) to high-caloric "snack foods" in rat strains genetically prone vs. resistant to diet-induced obesity: resistance to naltrexone blockade. Pharmacology, biochemistry, and behavior, 2007, Volume: 86, Issue:4 Topics: Animals; Conditioning, Psychological; Dietary Carbohydrates; Dietary Fats; Energy Intake; Food Preferences; Male; Naltrexone; Narcotic Antagonists; Obesity; Opioid Peptides; Rats; Rats, Sprague-Dawley	2007
The effect of kappa opioid receptor antagonism on energy expenditure in the obese Zucker rat. Biological research for nursing, 2007, Volume: 8, Issue:4 Topics: Analysis of Variance; Animals; Body Temperature; Body Weight; Calorimetry, Indirect; Cardiac Catheterization; Disease Models, Animal; Drug Evaluation, Preclinical; Energy Intake; Energy Metabolism; Injections, Intravenous; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Obesity; Rats; Rats, Zucker; Receptors, Opioid, kappa; Respiration; Telemetry	2007
Naltrexone reduces weight gain, alters "beta-endorphin", and reduces insulin output from pancreatic islets of genetically obese mice. Peptides, 1980,Winter, Volume: 1, Issue:4 Topics: Animals; beta-Endorphin; Body Weight; Endorphins; Insulin; Insulin Secretion; Islets of Langerhans; Mice; Mice, Obese; Naloxone; Naltrexone; Obesity; Pituitary Gland; Receptors, Opioid	1980
Nalmefene decreases meal size, food and water intake and weight gain in Zucker rats. Pharmacology, biochemistry, and behavior, 1983, Volume: 19, Issue:2 Topics: Animals; Appetite; Appetite Depressants; Body Weight; Drinking; Energy Intake; Female; Male; Naloxone; Naltrexone; Obesity; Rats; Rats, Zucker; Time Factors	1983
Effects of opioid antagonists naloxone and naltrexone on neuropeptide Y-induced feeding and brown fat thermogenesis in the rat. Neural site of action. The Journal of clinical investigation, 1995, Volume: 96, Issue:1 Topics: Adipose Tissue, Brown; Animals; Brain; Energy Metabolism; Feeding Behavior; Male; Naloxone; Naltrexone; Neuropeptide Y; Obesity; Paraventricular Hypothalamic Nucleus; Rats; Rats, Sprague-Dawley; Solitary Nucleus	1995
Reductions in body weight following chronic central opioid receptor subtype antagonists during development of dietary obesity in rats. Brain research, 1995, Apr-24, Volume: 678, Issue:1-2 Topics: Animals; Body Weight; Dietary Fats; Eating; Male; Naloxone; Naltrexone; Narcotic Antagonists; Obesity; Rats; Rats, Sprague-Dawley; Time Factors	1995
Effect of naltrexone treatment on insulin secretion, insulin action and postprandial thermogenesis in obesity. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1994, Volume: 26, Issue:4 Topics: Adult; Blood Glucose; Body Composition; Body Temperature Regulation; C-Peptide; Energy Metabolism; Female; Glucose Tolerance Test; Humans; Insulin; Islets of Langerhans; Male; Middle Aged; Models, Biological; Naltrexone; Obesity; Oxidation-Reduction	1994
Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants. Pharmacology, biochemistry, and behavior, 1993, Volume: 46, Issue:3 Topics: Albuterol; Animals; Appetite Depressants; Cyclohexanes; Dextroamphetamine; Drug Tolerance; Eating; Endorphins; Female; Fenfluramine; Injections, Subcutaneous; Male; Naltrexone; Obesity; Piperidines; Rats; Rats, Zucker; Weight Gain	1993
Long-term naltrexone treatment reduces the exaggerated insulin secretion in patients with polycystic ovary disease. Obstetrics and gynecology, 1993, Volume: 82, Issue:2 Topics: Adult; Endorphins; Female; Glucose Tolerance Test; Gonadal Steroid Hormones; Humans; Hyperinsulinism; Insulin; Naloxone; Naltrexone; Obesity; Polycystic Ovary Syndrome; Time Factors	1993
Differential response to kappa-opioidergic agents in dietary fat selection between Osborne-Mendel and S5B/P1 rats. Peptides, 1998, Volume: 19, Issue:1 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Non-Narcotic; Animals; Behavior, Animal; Brain; Diet; Dietary Fats; Eating; Energy Metabolism; Food Preferences; Male; Naltrexone; Narcotic Antagonists; Narcotics; Obesity; Rats; Rats, Inbred Strains; Receptors, Opioid, kappa	1998
Opioid receptor blockade promotes weight loss and improves the display of sexual behaviors in obese Zucker female rats. Pharmacology, biochemistry, and behavior, 1999, Volume: 63, Issue:3 Topics: Animals; Dose-Response Relationship, Drug; Eating; Estradiol; Female; Naltrexone; Narcotic Antagonists; Obesity; Ovariectomy; Progesterone; Rats; Rats, Zucker; Sexual Behavior, Animal; Steroids; Weight Loss	1999
Naltrexone does not prevent the weight gain and hyperphagia induced by the antipsychotic drug sulpiride in rats. Appetite, 2000, Volume: 34, Issue:1 Topics: Animals; Antipsychotic Agents; Diestrus; Eating; Female; Hyperphagia; Naltrexone; Narcotic Antagonists; Obesity; Rats; Rats, Wistar; Sulpiride; Weight Gain	2000
Effects of opiate agonists and an antagonist on food intake and brain neurotransmitters in normophagic and obese "cafeteria" rats. Pharmacology, biochemistry, and behavior, 1989, Volume: 34, Issue:3 Topics: Animals; Biogenic Monoamines; Brain; Dopamine; Endorphins; Feeding Behavior; Female; Naltrexone; Obesity; Rats; Rats, Inbred Strains; Receptors, Opioid; Serotonin	1989
Responses of lean and obese subjects to preloads, deprivation, and palatability. Appetite, 1989, Volume: 13, Issue:1 Topics: Adult; Eating; Feeding Behavior; Female; Food Deprivation; Humans; Male; Middle Aged; Naltrexone; Obesity; Taste; Thinness	1989
Influence of nalmefene on energy balance and glucose regulation in Zucker rats. Physiology & behavior, 1986, Volume: 37, Issue:6 Topics: Administration, Oral; Animals; beta-Endorphin; Blood Glucose; Endorphins; Energy Metabolism; Feeding Behavior; Female; Injections, Subcutaneous; Insulin; Male; Naltrexone; Narcotic Antagonists; Obesity; Rats; Rats, Zucker; Tolbutamide	1986
Action of naltrexone on the sexual impairment of obese cafeteria rats. NIDA research monograph, 1986, Volume: 75 Topics: Animals; Diet; Male; Naltrexone; Obesity; Rats; Rats, Inbred Strains; Reference Values; Sexual Behavior, Animal	1986
Effect of naltrexone on food intake, hunger, and satiety in obese men. Physiology & behavior, 1987, Volume: 40, Issue:2 Topics: Adolescent; Adult; Appetite; Drinking Behavior; Feeding Behavior; Humans; Hunger; Male; Middle Aged; Naltrexone; Obesity; Satiation; Satiety Response; Time Factors	1987